Vaccine Design and Testing – News and Features

Scientists have developed a new paper-based device that can improve the diagnosis of malaria in asymptomatic people. In field tests in Ghana, the device outperformed the current gold standard methods being used in the country's hospitals.

Multidisciplinary AI- and physics-driven modeling of the viral fusion process has enabled the discovery of an orally available drug inhibiting infection with multiple coronaviruses.

UConn researchers have demonstrated that a novel protein-based nanoparticle can make mRNA vaccines more effective in tackling a troublesome pathogen in chickens.

New research has found that adding IL-12, a cytokine produced by various immune cells, to mRNA vaccines improves T-cell responses. This could make the benefits of vaccines last longer.

A global study, covering more than 230 million people, sheds light on the relationship between Guillain-Barré syndrome after certain Covid vaccines or SARS-CoV-2 infection.

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study.

Scientists have used machine learning to improve the efficacy and safety of targeted cell and gene therapies by potentially using our own proteins. This tool could help to design proteins that avoid unwanted immune responses.

Moderna’s next-generation COVID-19 vaccine earns FDA approval for high-risk groups only. Learn what this could mean for future COVID-19 vaccine approvals.

A new material developed at Cornell could significantly improve the delivery and effectiveness of mRNA vaccines – used to fight COVID-19 – by replacing a commonly used ingredient that may trigger unwanted immune responses in some people.

Prior COVID-19 vaccination did not stop the immune system from mounting a protective response to the Delta and Omicron strains, though new mutation-specific antibody production dipped slightly, according to a study.